Founded in 1991, ImaRx Pharmaceutical Corp. designs, develops and markets pharmaceuticals for medical imaging (MRI, ultrasound and computed tomography) for the radiological imaging industry.
ImaRx Pharmaceutical Corp., announced 1999 that it has been acquired by E.I DuPont de Nemours & Co., Inc. The terms of the acquisition provide a royalty-free licensing arrangement with a newly-formed company, ImaRx LLC ('LLC'), to pursue and develop new products and technologies for drug and gene delivery independent from DuPont. Yamanouchi Pharmaceutical Co. Ltd., ImaRx' licensee for Asian territories for this product, will continue to develop the product in Asia as DuPont's licensee. ImaRx LLC will have ownership of all other targeted and therapeutic products previously owned by ImaRx, including imaging products outside of diagnostic ultrasound imaging and two other imaging products, SonoRx® and LumenHance®, which are both FDA approved and licensed to BRACCO Diagnostics.
See also Lantheus Medical Imaging and Definity®.

Ultrasound Contrast Agents:

From Bracco Diagnostics Inc
SonoRx® is a gas-shadowing reduction agent, used in abdominal ultrasound to enhance the delineation of upper abdominal anatomy. This ultrasound contrast agents is designed to adsorb and displace stomach and bowel gas and should be taken after fasting for at least four hours. Ingestion orally of the simethicone-coated cellulose suspension over 15 minutes in dosages of 200 to 400 ml results in a homogeneous transmission of sound through the contrast-filled stomach.
Bristol-Myers Squibb, under license from ImaRx LLC;; marketed by Bracco Diagnostics Inc, Source: FDA approvals - 11/03/98

MRX 115 is a liposome based microbubble formulation and has been demonstrated as effective for cardiac blood pool imaging, Doppler enhancement and potentially myocardial perfusion imaging.
MRX 115 is based upon the demand for a stable, robust blood pool ultrasound contrast agents, also called DMP 115 or Aerosomes™ (ImaRx LLC) and now Definity®.

MRX 408 is an investigational thrombus-specific ultrasound contrast agent for clot detection and sonothrombolysis enhancement. Targeted contrast imaging with this GPIIb receptor-targeted ultrasound contrast agent demonstrated better visualization of thrombus within AV fistulae.
MRX 408 is available (ImaRx LLC) with a mean radius of 1.0 mm and a standard deviation of 0.8 mm.